HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
Clinical trial NCT01777958 · COMPLETED
Trial details
- NCT number
- NCT01777958
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2013-06-14
- Primary completion
- 2020-11-25
- Enrollment
- 135
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.